Carvedilol reduces plasma 8-hydroxy-2′-deoxyguanosine in mild to moderate hypertension: A pilot study

Hypertension

Volumn 45, Issue 5, 2005, Pages 986-990

  Lee, Juyong ^a   Lee, Mejeong ^a   Kim, Jeong Uk ^a   Song, Kyung Il ^a   Choi, Yun Seok ^a   Cheong, Sang Sig ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Antioxidants

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA TOCOPHEROL; C REACTIVE PROTEIN; CARVEDILOL; GLUTATHIONE; PLACEBO; REACTIVE OXYGEN METABOLITE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPERTENSION; LIPID PEROXIDATION; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR SMOOTH MUSCLE;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; C-REACTIVE PROTEIN; CARBAZOLES; DEOXYGUANOSINE; DNA DAMAGE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PILOT PROJECTS; PROPANOLAMINES; SEVERITY OF ILLNESS INDEX;

EID: 18244384044     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000164569.63160.24     Document Type: Article

References (27)

1. Lawson JA. Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem. 1999;274:24441- 24444.
2. Lorch S, Lightfoot R, Ohshima H, Virag L, Chen Q, Hertkorn C, Weiss M, Souza J, Ischiropoulos H, Yermilov V, Pignatelli B, Masuda M, Szabo C. Detection of peroxynitrite-induced protein and DNA modifications. Methods Mol Biol. 2002;196:247-275.
3. Lee SH, Blair IA. Oxidative DNA damage and cardiovascular disease. Trends Cardiovasc Med. 2001;11:148-155.
4. Packer M, Bristow MR, Conn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (for US Carvedilol Heart Failure Study Group). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
5. Yue TL, Lysko PG, Barone FC, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive drug with unique antioxidant activity: potential role in cerebroprotection. Ann N Y Acad Sci. 1994;738:230-242.
6. Feuerstein G, Shusterman NH, Ruffolo RR Jr. Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression of congestive cardiac failure. Drugs Today. 1997;33:453-473.
7. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol. 1996;27:532-538.
8. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 2000;101:122-124.
9. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RE Jr, Feuerstein GZ. Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils, Cardiovasc Res. 1994;28:400-406.
10. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, Hiai H, Ochi H, Osawa T. Quantitative immunohistochemical determination of 8-hydroxy-2′ -deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest. 1997;76:365-374.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-2571.
12. Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther. 1997;11:247-256.
13. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
14. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1-9.
15. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996;347:444-445.
16. Crawford DW, Blankenhorn DH. Arterial wall oxygenation, oxyradicals, and atherosclerosis. Atherosclerosis. 1991;89:97-108.
17. Sharma RC, Crawford DW, Kramsch DM, Sevanian A, Jiao Q. Immunolocalization of native antioxidant scavenger enzymes in early hypertensive and atherosclerotic arteries. Role of oxygen free radicals. Arterioscler Thromb. 1992;12:403-415.
18. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA. 1991;88:10045-10048.
19. Bellelli G, Rozzini R, Battista Frisoni G, Trabucchi M. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:2107.
20. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res. 2003;26:691-697.
21. Touyz RM. Reactive oxygen species, vascular oxidantive stress, and redox signialing in hypertension, what is the clinical significance? Hypertension. 2004;44:248-252.
22. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-1916.
23. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med. 2002;32:1102-1115.
24. Shimoi K, Kasai H, Yokota N, Toyokuni S, Kinae N. Comparison between high-performance liquid chromatography and enzyme-linked immunosorbent assay for the determination of 8-hydroxy-2′-deoxyguanosine in human urine. Cancer Epidemiol Biomarkers Prev. 2002;11:767-770.
25. Harman SM, Liang L, Tsitouras PD, Gucciardo F, Reward CB, Reaven PD, Ping W, Ahmed A, Cutler RG. Urinary excretion of three nucleic acid oxidation adducts and isoprostane F(2)alpha measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and non-smokers. Free Radic Biol Med. 2003;35:1301-1309.
26. Sakamoto W, Isomura H, Fujie K, Nishihira J, Ozaki M, Yukawa S. Coffee increases levels of urinary 8-hydroxydeoxyguanosine in rats. Toxicology. 2003;183:255-263.
27. Cracowski JL, Baguet JP, Ormezzano O, Bessard J, Stanke-Labesque F, Bessard G, Mallion JM. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension. 2003;41:286-288.